

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1.-36. (canceled)

37. (New): A composition for treating lung diseases selected from the group consisting of acute pneumonia, pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPT), and asthma, comprising (E)-[5-[2-[1-phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid in a dose which is sufficient to treat such disease.

38. (New): The composition according to claim 37 wherein the lung disease is pulmonary fibrosis.

39. (New): The composition according to claim 37, wherein the lung disease is pulmonary hypertension.

40. (New): The composition according to claim 37, which is a persistent preparation which further comprises a biodegradable polymer.

41. (New): The composition according to claim 40, wherein the persistent preparation is a microsphere preparation, a microcapsule preparation or a nanosphere preparation.
42. (New): A composition for treating lung diseases selected from the group consisting of acute pneumonia, pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), and asthma, comprising (E)-[5-[2-[1 -phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid in a dose which is sufficient to accelerate production of VEGF and/or HGF.
43. (New): The composition according to claim 42, wherein the lung disease is pulmonary fibrosis.
44. (New): The composition according to claim 42, wherein the lung disease is pulmonary hypertension.
45. (New): The composition according to claim 42, which is a persistent preparation which further comprises a biodegradable polymer.
46. (New): The composition according to claim 45, wherein the persistent preparation is a microsphere preparation, a microcapsule preparation or a nanosphere preparation.
47. (New): A method of treating lung diseases selected from the group consisting of acute pneumonia, pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease

(COPD), and asthma, comprising administering to a patient in need of treatment an effective amount of (E)-[5-[2-[1 -phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid.

48. (New): The method according to claim 47, wherein the lung disease is pulmonary fibrosis.

49. (New): The method according to claim 47, wherein the lung disease is pulmonary hypertension.

50. (New): A method of treating lung diseases selected from the group consisting of acute pneumonia, pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), and asthma, comprising administering to a patient in need of treatment an effective amount of (E)-[5-[2-[1 -phenyl-1-(3-pyridyl)methylideneaminoxy]ethyl]-7,8-dihydronaphthalen-1-yloxy]acetic acid, whereby production of VEGF and/or HGF is accelerated.

51. (New): The method according to claim 50, wherein the lung disease is pulmonary fibrosis.

52. (New): The method according to claim 50, wherein the lung disease is pulmonary hypertension.